GT201400288A - "compuestos de fenoxietil piperidina" - Google Patents

"compuestos de fenoxietil piperidina"

Info

Publication number
GT201400288A
GT201400288A GT201400288A GT201400288A GT201400288A GT 201400288 A GT201400288 A GT 201400288A GT 201400288 A GT201400288 A GT 201400288A GT 201400288 A GT201400288 A GT 201400288A GT 201400288 A GT201400288 A GT 201400288A
Authority
GT
Guatemala
Prior art keywords
compounds
piperidine
phenoxietil
composites
intermediaries
Prior art date
Application number
GT201400288A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201400288A publication Critical patent/GT201400288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201400288A 2012-06-29 2014-12-17 "compuestos de fenoxietil piperidina" GT201400288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
GT201400288A true GT201400288A (es) 2015-08-27

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400288A GT201400288A (es) 2012-06-29 2014-12-17 "compuestos de fenoxietil piperidina"

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
HUE035698T2 (en) * 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102861190B1 (ko) * 2019-01-22 2025-09-17 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
CA2536870C (en) * 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CA2789665C (en) 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2729141B1 (en) * 2011-07-04 2015-12-09 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor agonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
DOP2014000287A (es) 2015-01-31
AU2013280875A1 (en) 2014-12-04
AP2014008164A0 (en) 2014-12-31
KR101653476B1 (ko) 2016-09-01
ZA201408632B (en) 2017-06-28
HRP20171515T1 (hr) 2017-11-17
JO3296B1 (ar) 2018-09-16
SG11201408641UA (en) 2015-01-29
NZ701933A (en) 2017-01-27
PH12015500009B1 (en) 2020-10-09
ME02840B (me) 2018-01-20
PT2867207T (pt) 2017-11-01
PE20150182A1 (es) 2015-02-13
US8962659B2 (en) 2015-02-24
UA114325C2 (uk) 2017-05-25
HUE034425T2 (en) 2018-02-28
BR112014031616A2 (pt) 2017-06-27
RS56452B1 (sr) 2018-01-31
US9402838B2 (en) 2016-08-02
US20140005226A1 (en) 2014-01-02
AR091429A1 (es) 2015-02-04
DK2867207T3 (en) 2017-09-11
PH12015500009A1 (en) 2015-03-02
IL236219A (en) 2017-12-31
HK1203937A1 (en) 2015-11-06
TWI599561B (zh) 2017-09-21
MX2014015953A (es) 2015-07-17
PL2867207T3 (pl) 2018-01-31
AU2013280875B2 (en) 2015-09-24
JP2015522018A (ja) 2015-08-03
CL2014003535A1 (es) 2015-05-08
CR20140553A (es) 2015-02-04
MX345324B (es) 2017-01-25
CN104411684B (zh) 2016-08-24
CO7151507A2 (es) 2014-12-29
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
MA37686A1 (fr) 2016-09-30
TN2014000501A1 (en) 2016-03-30
BR112014031616B1 (pt) 2022-06-21
WO2014004229A1 (en) 2014-01-03
EA024392B1 (ru) 2016-09-30
ES2644812T3 (es) 2017-11-30
MY173878A (en) 2020-02-26
EA201492255A1 (ru) 2015-03-31
SI2867207T1 (sl) 2017-10-30
JP6127136B2 (ja) 2017-05-10
IL236219A0 (en) 2015-02-01
CA2875569C (en) 2016-04-19
EP2867207B1 (en) 2017-08-09
CA2875569A1 (en) 2014-01-03
CY1119425T1 (el) 2018-03-07
US20150126555A1 (en) 2015-05-07
MA37686B1 (fr) 2017-04-28
KR20150013893A (ko) 2015-02-05
TW201412717A (zh) 2014-04-01
LT2867207T (lt) 2017-10-10
EP2867207A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CR20140553A (es) Compuestos de fenoxietil piperidina
PT2877184T (pt) Composições e tratamento para doenças e distúrbios oculares
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
PE20151067A1 (es) Inhibidores de autotaxina
GT201400242A (es) "nuevos compuestos de pirazol"
MX2015003140A (es) Formulaciones de enzalutamida.
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
SMT201600406B (it) Derivati della 8-carbamoil-2-(pirid-6-il-2,3-disostituito)-1,2,3,4-tetraidroisochinolina come agenti inducenti apoptosi per il trattamento del cancro e di malattie immunitarie e autoimmunitarie
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
CR20140573A (es) Inhibidores del nampt
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos